

# Irene Cassaniti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4016573/irene-cassaniti-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58  
papers

1,192  
citations

17  
h-index

34  
g-index

76  
ext. papers

1,885  
ext. citations

7.9  
avg, IF

4.7  
L-index

| #  | Paper                                                                                                                                                                                                                             | IF   | Citations |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 58 | Immunity to SARS-CoV-2 up to 15 months after infection.. <i>IScience</i> , <b>2022</b> , 25, 103743                                                                                                                               | 6.1  | 15        |
| 57 | Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , <b>2022</b> , 43, 103170               | 2.8  | 7         |
| 56 | SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment.. <i>Transfusion and Apheresis Science</i> , <b>2022</b> , 103398                                         | 2.4  | 0         |
| 55 | Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.. <i>BMC Medicine</i> , <b>2022</b> , 20, 102                                                         | 11.4 | 6         |
| 54 | Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital. <i>Vaccines</i> , <b>2022</b> , 10, 703 | 5.3  | 0         |
| 53 | Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, "Am like a Box of Complexity, You Never Know What You Are Gonna Get" <i>Vaccines</i> , <b>2022</b> , 10, 731                                          | 5.3  |           |
| 52 | Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.. <i>Nature Communications</i> , <b>2022</b> , 13, 2670                                    | 17.4 | 8         |
| 51 | Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients.. <i>Journal of Voice</i> , <b>2021</b> ,                                                                                   | 1.9  | 8         |
| 50 | SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. <i>Nature Communications</i> , <b>2021</b> , 12, 6032                                         | 17.4 | 16        |
| 49 | Macrophages and Monocytes: "Trojan Horses" in COVID-19. <i>Viruses</i> , <b>2021</b> , 13,                                                                                                                                        | 6.2  | 3         |
| 48 | EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 104, 315-319                                                              | 10.5 | 22        |
| 47 | Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. <i>Clinical and Experimental Medicine</i> , <b>2021</b> , 21, 379-388                                                         | 4.9  | 1         |
| 46 | Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. <i>Med</i> , <b>2021</b> , 2, 281-295.e4                                                              | 31.7 | 74        |
| 45 | Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , <b>2021</b> , 593, 424-428                                                                                                            | 50.4 | 36        |
| 44 | SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation. <i>Journal of Hospital Infection</i> , <b>2021</b> , 110, 33-36                                                               | 6.9  | 11        |
| 43 | A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 1774-1784       | 6.1  | 9         |
| 42 | Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 914.e1-914.e4                                | 9.5  | 1         |

|    |                                                                                                                                                                                                                                                                                          |      |     |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 41 | Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1635-1638                  | 2.4  | 21  |
| 40 | SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 1029-1034                                                                                 | 9.5  | 19  |
| 39 | Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. <i>Stem Cells Translational Medicine</i> , <b>2021</b> , 10, 636-642                                                                                                     | 6.9  | 17  |
| 38 | Dynamic angiotensin-converting enzyme 2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. <i>Blood Advances</i> , <b>2021</b> , 5, 662-673                                                                                                         | 7.8  | 17  |
| 37 | Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1622-1628                                                                                            | 8.7  | 9   |
| 36 | Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 1708-1709                                                                                         | 9.5  | 1   |
| 35 | Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays. <i>Vaccines</i> , <b>2021</b> , 9,                                                                                 | 5.3  | 2   |
| 34 | Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 109, 199-202 | 10.5 | 10  |
| 33 | Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , <b>2021</b> ,                                                                   | 9.5  | 11  |
| 32 | Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 994                                                              | 4    | 1   |
| 31 | A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. <i>ESMO Open</i> , <b>2021</b> , 6, 100272                                                | 6    | 12  |
| 30 | Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo Covid19 REgistry (SMACORE). <i>Microorganisms</i> , <b>2020</b> , 8,                                                                                                                             | 4.9  | 157 |
| 29 | Emergency Department and Out-of-Hospital Emergency System (112-AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 825-833                                                                  | 3.7  | 31  |
| 28 | Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. <i>Journal of Hospital Infection</i> , <b>2020</b> ,                                                                                                       | 6.9  | 39  |
| 27 | Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. <i>Journal of Hospital Infection</i> , <b>2020</b> ,                                                                                            | 6.9  | 22  |
| 26 | Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 1724-1727                                                                   | 19.7 | 152 |
| 25 | SARS Cov-2 infection in a renal-transplanted patient: A case report. <i>American Journal of Transplantation</i> , <b>2020</b> , 20, 1882-1884                                                                                                                                            | 8.7  | 67  |
| 24 | Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. <i>Hematological Oncology</i> , <b>2020</b> , 38, 554-559                                                                                                               | 1.3  | 2   |

|    |                                                                                                                                                                                                                                       |      |     |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 23 | SARS-CoV-2 positivity in rectal swabs: implication for possible transmission. <i>Journal of Global Antimicrobial Resistance</i> , <b>2020</b> , 22, 754-755                                                                           | 3.4  | 8   |
| 22 | West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors. <i>Viruses</i> , <b>2020</b> , 12,                                                                         | 6.2  | 19  |
| 21 | CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 16                                                                                                  | 8.4  | 0   |
| 20 | Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,                                         | 19.8 | 86  |
| 19 | Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,                                                 | 19.8 | 114 |
| 18 | Authors' response: COVID-19: how accurate are seroprevalence studies?. <i>Eurosurveillance</i> , <b>2020</b> , 25,                                                                                                                    | 19.8 | 1   |
| 17 | Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. <i>Clinical Microbiology and Infection</i> , <b>2020</b> , 26, 1094.e1-1094.e5           | 9.5  | 86  |
| 16 | Dengue Virus-Specific Humoral and T Cellular Immune Response in Italian Residents and Travelers Returning from Endemic Areas. <i>Vector-Borne and Zoonotic Diseases</i> , <b>2020</b> , 20, 295-302                                   | 2.4  | 2   |
| 15 | Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. <i>Clinical Microbiology and Infection</i> , <b>2020</b> , 26, 1569-1571                | 9.5  | 2   |
| 14 | SARS-CoV-2 Virologic and Immunologic Correlates in Patients with Olfactory and Taste Disorders. <i>Microorganisms</i> , <b>2020</b> , 8,                                                                                              | 4.9  | 2   |
| 13 | Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. <i>Pediatric Allergy and Immunology</i> , <b>2020</b> , 31, 72-74                                                | 4.2  | 3   |
| 12 | Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay. <i>Journal of Immunology Research</i> , <b>2019</b> , 2019, 4236503 | 4.5  | 11  |
| 11 | Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib. <i>Blood</i> , <b>2019</b> , 134, 1660-1660                                                            | 2.2  | 0   |
| 10 | Zika Virus Infection in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and Possible Implication for Cross-Reactivity and Cross-Protection. <i>Microorganisms</i> , <b>2019</b> , 8,  | 4.9  | 2   |
| 9  | Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017. <i>Clinical Microbiology and Infection</i> , <b>2019</b> , 25, 526-528                                                   | 9.5  | 5   |
| 8  | Human Cytomegalovirus-Specific Memory CD4+ T-Cell Response and Its Correlation With Virus Transmission to the Fetus in Pregnant Women With Primary Infection. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 1659-1665       | 11.6 | 15  |
| 7  | Chemotherapy to induce T-cell subpopulation changes in advanced breast cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e12562-e12562                                                                        | 2.2  | 1   |
| 6  | Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects. <i>Human Vaccines and Immunotherapeutics</i> , <b>2016</b> , 12, 2927-2933                  | 4.4  | 6   |

|   |                                                                                                                                                                         |   |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 5 | Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant | 5 |
| 4 | Immunity to SARS-CoV-2 up to 15 months after infection                                                                                                                  | 3 |
| 3 | Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection                                             | 2 |
| 2 | SARS-CoV-2 mRNA vaccine BNT162b2 elicited a robust humoral and cellular response against SARS-CoV-2 variants.                                                           | 5 |
| 1 | SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers                                      | 1 |